ROIV Stock Forecast & Price Target

Roivant Sciences is underpinned by a diversified, high-upside pipeline that now includes commercial-stage VTAMA and multiple late-stage clinical assets, with mosliciguat emerging as a major catalyst after PHocus showed a 56.3% placebo-adjusted PVR reduction, +35.2 meters in 6MWD, and a 53.2% NT-proBNP decline at Week 16. The data are especially compelling because PH-ILD has a median survival of just 1.5-2 years, approved therapy penetration remains below 20%, and management is advancing Phase III PHrontier with approximately 375 patients while allowing background treprostinil. In addition, the company’s valuation framework assigns meaningful contribution from IMVT-1402, brepocitinib, and an anticipated YE26 net cash position, while Lisraya’s immediate commercial availability in dermatomyositis strengthens the near-term execution story.

Roivant Sciences is facing a fundamentally weakened outlook because several pipeline assets have failed in clinical trials, including IMVT programs in non-infectious uveitis and cutaneous sarcoidosis, as well as mosliciguat in PH-ILD. The company also faces unanticipated safety issues across batoclimab, IMVT-1402, brepocitinib, and other assets, which raises doubts about the viability and timeline of its broader development portfolio. In addition, litigation setbacks, unaudited financial statements, and other R&D, regulatory, or commercial setbacks increase execution risk and reduce confidence in the durability of future value creation.